152 related articles for article (PubMed ID: 7586731)
21. Impact of small molecules immunosuppressants on P-glycoprotein activity and T-cell function.
Llaudó I; Cassis L; Torras J; Bestard O; Franquesa Ml; Cruzado JM; Cerezo G; Castaño E; Pétriz J; Herrero-Fresneda I; Grinyó JM; Lloberas N
J Pharm Pharm Sci; 2012; 15(3):407-19. PubMed ID: 22974789
[TBL] [Abstract][Full Text] [Related]
22. Suppression of adult T cell leukemia-derived factor/human thioredoxin induction by FK506 and cyclosporin A: a new mechanism of immune modulation via redox control.
Furuke K; Nakamura H; Hori T; Iwata S; Maekawa N; Inamoto T; Yamaoka Y; Yodoi J
Int Immunol; 1995 Jun; 7(6):985-93. PubMed ID: 7577807
[TBL] [Abstract][Full Text] [Related]
23. Rapamycin blocks cell cycle progression of activated T cells prior to events characteristic of the middle to late G1 phase of the cycle.
Terada N; Lucas JJ; Szepesi A; Franklin RA; Domenico J; Gelfand EW
J Cell Physiol; 1993 Jan; 154(1):7-15. PubMed ID: 8419408
[TBL] [Abstract][Full Text] [Related]
24. The hydroxylamine of sulfamethoxazole synergizes with FK506 and cyclosporin A, inhibiting T-cell proliferation.
Hess DA; Bird IA; Almawi WY; Rieder MJ
J Pharmacol Exp Ther; 1997 Apr; 281(1):540-8. PubMed ID: 9103542
[TBL] [Abstract][Full Text] [Related]
25. Interleukin-2 receptor (CD25) upregulation on human T-lymphocytes: sensitivity to immunosuppressants is defined by the mode of T-lymphocyte activation.
Ryffel B; Willcocks JL; Brooks N; Woerly G
Immunopharmacology; 1995 Sep; 30(3):199-207. PubMed ID: 8557519
[TBL] [Abstract][Full Text] [Related]
26. Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis.
Koenen HJ; Michielsen EC; Verstappen J; Fasse E; Joosten I
Transplantation; 2003 May; 75(9):1581-90. PubMed ID: 12792519
[TBL] [Abstract][Full Text] [Related]
27. Preferential increase in memory and regulatory subsets during T-lymphocyte immune reconstitution after Thymoglobulin induction therapy with maintenance sirolimus vs cyclosporine.
Morelon E; Lefrançois N; Besson C; Prévautel J; Brunet M; Touraine JL; Badet L; Touraine-Moulin F; Thaunat O; Malcus C
Transpl Immunol; 2010 May; 23(1-2):53-8. PubMed ID: 20406686
[TBL] [Abstract][Full Text] [Related]
28. Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists.
Hatfield SM; Mynderse JS; Roehm NW
J Pharmacol Exp Ther; 1992 Jun; 261(3):970-6. PubMed ID: 1376361
[TBL] [Abstract][Full Text] [Related]
29. The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma.
Haczku A; Alexander A; Brown P; Assoufi B; Li B; Kay AB; Corrigan C
J Allergy Clin Immunol; 1994 Feb; 93(2):510-9. PubMed ID: 8120277
[TBL] [Abstract][Full Text] [Related]
30. Anti-CD3 antibodies OKT3 and hOKT3gamma1(Ala-Ala) induce proliferation of T cells but impair expansion of alloreactive T cells; aspecifc T cell proliferation induced by anti-CD3 antibodies correlates with impaired expansion of alloreactive T cells.
Popma SH; Griswold DE; Li L
Int Immunopharmacol; 2005 Jan; 5(1):155-62. PubMed ID: 15589476
[TBL] [Abstract][Full Text] [Related]
31. Induction of CD5 on B and T cells is suppressed by cyclosporin A, FK-520 and rapamycin.
Teutsch M; Higer M; Wang D; Wortis HW
Int Immunol; 1995 Mar; 7(3):381-92. PubMed ID: 7540861
[TBL] [Abstract][Full Text] [Related]
32. Effect of rapamycin on the in vitro release of soluble interleukin-2 receptor by phytohemagglutinin, phorbol myristate acetate, and ionomycin-activated peripheral blood mononuclear cells.
Barkis I; Hadjiyannaki-Koniavitou K; Vareltzides A; Hornung N; Raskova J; Degiannis D
Transplant Proc; 1995 Feb; 27(1):432-4. PubMed ID: 7879050
[No Abstract] [Full Text] [Related]
33. Effect of cyclosporin A, FK506 and rapamycin on proliferation and soluble IL-2 receptor release from mitogenically stimulated rat spleen cells.
Pockley AG; Williams S; Reid SD; Bowles MJ
Biochem Soc Trans; 1995 Nov; 23(4):615S. PubMed ID: 8654800
[No Abstract] [Full Text] [Related]
34. IL-2 responsiveness of lectin-induced lymphoblasts: soluble IL-2 receptor release and differential in vitro effects of immunosuppressants.
Hornung N; Raskova J; Raska K; Degiannis D
Int J Immunopharmacol; 1992 Jul; 14(5):753-60. PubMed ID: 1512072
[TBL] [Abstract][Full Text] [Related]
35. Induction of IL-5 expression by IL-2 is resistant to the immunosuppressive agents cyclosporin A and rapamycin.
Valentine JE; Sewell WA
Int Immunol; 1997 Jul; 9(7):975-82. PubMed ID: 9237106
[TBL] [Abstract][Full Text] [Related]
36. Additional inhibitory effects of intravenous immunoglobulins in combination with cyclosporine A on human T lymphocyte alloproliferative response in vitro.
Schanz U; Hügle T; Gmür J
Transplantation; 1996 Jun; 61(12):1736-40. PubMed ID: 8685953
[TBL] [Abstract][Full Text] [Related]
37. Effects of anti-interleukin-2 receptor antibody and cyclosporin A on human T cell proliferation in primary mixed lymphocyte reaction.
Oiwa K; Sakagami K; Orita K
Hiroshima J Med Sci; 1989 Mar; 38(1):1-6. PubMed ID: 2526799
[TBL] [Abstract][Full Text] [Related]
38. Immunosuppressive effects of defibrotide.
Ferraresso M; Rigotti P; Stepkowski SM; Chou TC; Kahan BD
Transplantation; 1993 Oct; 56(4):928-33. PubMed ID: 8212219
[TBL] [Abstract][Full Text] [Related]
39. In vitro immunomodulatory activity of ruthenium complexes.
Newcomb JR; Rivnay B; Bastos CM; Ocain TD; Gordon K; Gregory P; Turci SM; Sterne KA; Jesson M; Krieger J; Jenson JC; Jones B
Inflamm Res; 2003 Jun; 52(6):263-71. PubMed ID: 12835898
[TBL] [Abstract][Full Text] [Related]
40. The effect of the CD28 activation pathway on the immunosuppressive action of cyclosporine.
Hess AD; Bright EC
Transplantation; 1991 Jun; 51(6):1232-40. PubMed ID: 1646506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
